Derma Sciences to Present at the Lazard Capital Markets 8th Annual Healthcare Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will be presenting at the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November 15, 2011 at 3:00 p.m. ET. The conference is being held September 15-16, 2011 at the Pierre Hotel in New York City. Edward J. Quilty, Chairman and CEO, will deliver the Company's corporate presentation.

The presentation will be webcast live at http://wsw.com/webcast/lz11/dsci/ and on the Investor Relations section of the Company's website at www.dermasciences.com, where it will also be archived for 90 days.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention.

For more information please visit www.dermasciences.com.

Derma Sciences, Inc. (NASDAQ:DSCI)
Historical Stock Chart
From Apr 2024 to May 2024